savuconazonium Sulfate Capsules

Isavuconazole sulfate capsules can usually control the progression of the disease and help treat related diseases caused by fungal infections. You need to follow the doctor’s instructions when taking the medicine.

Isavuconazole sulfate capsules are an antifungal drug, usually used to treat some serious fungal infection symptoms. If there are superficial fungal infections, tropical fungal infections, invasive fungal infections and other diseases, using this drug can help control the symptoms. Since the main ingredient of the drug is isavuconazole, it belongs to a wide range of fungi, and the drug has an inhibitory effect on bacteria, fungi or Candida albicans. However, you need to follow the doctor’s instructions when taking the medicine. Due to the different physical conditions of each person, the specific medication effects are different.

During the treatment, you need to pay attention to a light diet and try not to eat some irritating foods.

Excipients: mannitol, sulfuric acid (for pH adjustment)

[Properties] This product is a white to yellow block.

[Indications] This product is suitable for the treatment of the following infections in adult patients:

• Invasive aspergillosis

• Invasive mucormycosis

[Specifications] 200mg (calculated as C22H17F2N5OS)

[Usage and Dosage] Dosage

Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained before starting antifungal treatment to isolate and identify pathogenic microorganisms. Early targeted treatment (preemptive treatment or diagnosis-driven treatment) can be started while waiting for specific diagnostic tests to confirm the disease. However, after the results are available, antifungal treatment should be adjusted accordingly.

Loading dose: Recommended loading dose: One bottle (equivalent to 200 mg of isavuconazole) every 8 hours within the first 48 hours, administered after reconstitution and dilution, for a total of 6 doses.

Maintenance dose: Recommended maintenance dose: One bottle (equivalent to 200 mg of isavuconazole) once a day starting 12 to 24 hours after the last loading dose, administered after reconstitution and dilution.

The duration of treatment should be determined based on clinical response (see [Clinical Trials]).

For long-term treatment of more than 6 months, the benefit-risk balance should be carefully considered (see [Clinical Trials] and [Pharmacology and Toxicology]).

Interchange between oral capsules and intravenous infusion: This product is also available in capsule form, each containing 100 mg of isavuconazole. (See “Instructions for Use of Isavuconazole Sulfate Capsules” for use)

Due to the high bioavailability of the oral dosage form (98%, see [Pharmacokinetics]), the two routes of administration, intravenous infusion and oral administration, can be interchanged when clinically indicated.

Medication for special populations

Elderly: Elderly patients do not need to adjust the dose; however, clinical experience with elderly patients is limited.

Renal impairment: Patients with renal impairment (including patients with end-stage renal disease) do not need to adjust the dose (see [Pharmacokinetics]).

Hepatic impairment: Patients with mild or moderate hepatic impairment (Child-Pugh A and B) do not need to adjust the dose (see [Precautions], [Pharmacokinetics]).

Isavuconazole has not been studied in patients with severe hepatic impairment (Child-Pugh class C). Its use in these patients is not recommended unless the potential benefits are considered to outweigh the risks (see Precautions, Adverse Reactions, Pharmacokinetics).

Pediatric population: The safety and efficacy of this product in minors under 18 years of age have not been established. No data are available.